Synthetic biology is predicted to be a £62bn market by 2020
There’s never been a better time to invest in synthetic biology.
Today Europe is the base for almost a third of the world’s synthetic biology start-ups and attracted more than $207 million USD in private investment in 2015 alone. The U.K. government has placed synthetic biology among ‘Eight Great Technologies’ and invested £150 million in research and training during the last four years. The research output from this on-going investment is poised for translation from the lab to the market.
The U.K. is well positioned to exploit this development, with our companies contributing nearly 10% of the global biopharmaceutical pipeline. With world-leading scientists and an entrepreneurial culture in the UK, pioneering synthetic biology start-ups have already delivered returns to investors.
UK successes stories such as the Intrexon (NYSE:XON) purchase of Oxford start-up Oxitec and growth of the gene-editing company Horizon Discovery Group (LSE:HZD) have heralded an explosion of new home-grown companies with offerings spanning novel therapeutic treatments to new biomaterials. SynbiCITE can help you navigate this sector and identify the right synthetic biology investment opportunity for you.
SynbiCITE can help your company realise the economic potential of synthetic biology in many ways:
We’re a not-for-profit independent, perfectly placed to assess and monitor the business and scientific viability of emerging start-ups. We can provide written reports or verbal feedback, as well as the training and resources to ready businesses for investment.
Our network of thousands of experts can give you valuable intelligence about the synthetic biology marketplace in the U.K. and globally. Our collaborative reach is international, with strong links to Europe and the United States.
Investor information. For investors wanting information and data on the vibrant and exciting synthetic biology startup community in UK, we are your first point of call.
SynbiCITE provides a yearly snapshot of the health of the UK synthetic biology startup sector in its publication of SynbiCITE’s Annual UK Synthetic Biology Startup Report.
The publication produced by SynbiCITE looks at where and what type of companies are being formed; where investment is going and how research outputs from the synthetic biology research centres are being translated. If you would like a copy, please click here – fill in personal details page - to access pdf
SynbiCITE Investor Network (SIN) is a business angels network for investors and private companies interested in investing in startup companies working with synthetic biology. It provides a vehicle from which private individuals and companies can meet, discuss and invest in the early stages startup companies. Established in 2016, the SynbiCITE Investor Network (SIN) is a not-for-profit company limited by guarantee. Access to SIN is currently free, and open to both investment professionals and private investors.
Membership entitles you to receive:
- Business proposals circulated on behalf of pre-seed and early stage companies looking for funding
- Invitations to our regular Investment Meetings, at which both early-stage and established spin-out companies present their funding opportunities.
- Invitations to special investor events. This year we held a SynbiCITE Investor Breakfast, hosted by Lord Willetts, at the House of Lords. This provided investors to hear from leading figures and companies in synthetic biology discuss the new opportunities and products.